Catalyst Wire Dossier Catalyst Wire Dossier
EMA withdrawal · 2013-05-17

EMA Application withdrawn: Fanaptum (iloperidone) — Vanda Pharmaceuticals Ltd

View source ↗

Summary

The EMA withdrew the application for Fanaptum (iloperidone) by Vanda Pharmaceuticals Ltd for schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Fanaptum (iloperidone)

Snippet

Status: Application withdrawn. Therapeutic area: Schizophrenia. MAH: Vanda Pharmaceuticals Ltd. Decision date: 14/12/2012